Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CEO Michael J. Rossi Sells 3,917 Shares

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CEO Michael J. Rossi sold 3,917 shares of the firm’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.20, for a total value of $20,368.40. Following the transaction, the chief executive officer now owns 137,083 shares of the company’s stock, valued at $712,831.60. This trade represents a 2.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ YMAB opened at $4.94 on Wednesday. Y-mAbs Therapeutics, Inc. has a fifty-two week low of $4.25 and a fifty-two week high of $17.78. The firm has a market capitalization of $223.38 million, a PE ratio of -9.15 and a beta of 0.65. The stock’s 50-day simple moving average is $6.22 and its 200-day simple moving average is $10.38.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The firm had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period last year, the firm earned ($0.02) EPS. On average, sell-side analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Infinitum Asset Management LLC acquired a new position in Y-mAbs Therapeutics during the fourth quarter worth approximately $1,218,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Y-mAbs Therapeutics by 17.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 52,356 shares of the company’s stock worth $410,000 after buying an additional 7,765 shares during the period. Two Sigma Investments LP increased its position in Y-mAbs Therapeutics by 31.6% during the fourth quarter. Two Sigma Investments LP now owns 88,337 shares of the company’s stock worth $692,000 after buying an additional 21,196 shares during the period. Rafferty Asset Management LLC increased its position in Y-mAbs Therapeutics by 17.6% during the fourth quarter. Rafferty Asset Management LLC now owns 41,255 shares of the company’s stock worth $323,000 after buying an additional 6,178 shares during the period. Finally, ProShare Advisors LLC purchased a new position in shares of Y-mAbs Therapeutics in the 4th quarter valued at approximately $99,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Morgan Stanley lowered their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday, March 5th. Oppenheimer initiated coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 target price for the company. Wedbush reiterated an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Bank of America decreased their price objective on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Wednesday, March 5th. Finally, Truist Financial decreased their price objective on Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.30.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.